Inogen (INGN) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings or view top-rated stocks.

3 brokers have issued twelve-month price objectives for Inogen's stock. Their INGN share price forecasts range from $22.00 to $26.00. On average, they expect the company's share price to reach $24.00 in the next year. This suggests a possible upside of 124.7% from the stock's current price.
View analysts price targets for INGN or view top-rated stocks among Wall Street analysts.

Inogen's stock was trading at $19.71 on January 1st, 2023. Since then, INGN shares have decreased by 45.8% and is now trading at $10.68.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our INGN earnings forecast.

Inogen, Inc. (NASDAQ:INGN) posted its earnings results on Thursday, May, 4th. The medical technology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.14. The medical technology company had revenue of $72.16 million for the quarter, compared to analyst estimates of $74.68 million. Inogen had a negative trailing twelve-month return on equity of 11.06% and a negative net margin of 24.36%. Inogen's quarterly revenue was down 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.38) earnings per share.

ETFs with the largest weight of Inogen (NASDAQ:INGN) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Cultivar ETF (CVAR), Syntax Stratified SmallCap ETF (SSLY), Invesco S&P SmallCap Health Care ETF (PSCH), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Medical Devices ETF (IHI),

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.20%), Brown Capital Management LLC (9.55%), Fred Alger Management LLC (4.86%), State Street Corp (4.65%), Dimensional Fund Advisors LP (3.72%) and Geode Capital Management LLC (1.95%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends.

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INGN stock can currently be purchased for approximately $10.68.

Inogen (NASDAQ:INGN) has a market capitalization of $246.93 million and generates $369.02 million in revenue each year. The medical technology company earns $-83,770,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

The company employs 1,026 workers across the globe.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net.